NCT07382167Phase 3Recruiting

A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

Study sponsor: Ardelyx

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-02-26Estimated

Enrollment · participants692Estimated

Source updated2026-06-04Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-03-17 · 1 field changed

Primary outcomes · main study measures

Text edit · unverified significance

− Previous value

measure: Durable CSBM response

+ Updated value

measure: Durable complete spontaneous bowel movements (CSBM) response

The saved outcome text may be shortened. Check the source for full wording.

Check registry source

Study details

Conditions studied

Chronic Idiopathic Constipation (CIC)

Treatments or interventions studied

Tenapanor 5 mg BIDDrug
Tenapanor 25 mg BIDDrug
Tenapanor 50 mg BIDDrug
PlaceboDrug

Primary outcomes · main study measures

measure: Durable complete spontaneous bowel movements (CSBM) response; description: Durable complete spontaneous bowel movements (CSBM) response is defined as achieving the weekly CSBM response for ≥9 out of the first 12 weeks of the randomized treatment period and and for ≥3 of the last 4 weeks of the first 12 weeks of randomized treatment period; timeFrame: 12 Weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history